South Carolina Department of Health and Human Services Post Office Box 8206 Columbia, South Carolina

Similar documents
South Carolina Department of Health and Human Services Post Office Box 8206 Columbia, South Carolina

South Carolina Department of Health and Human Services Post Office Box 8206 Columbia, South Carolina

South Carolina Department of Health and Human Services Post Office Box 8206 Columbia, South Carolina

SmithRx Standard Formulary Step Therapy List

South Carolina Department of Health and Human Services Post Office Box 8206 Columbia, South Carolina

Commissioner for the Department for Medicaid Services Selections for Preferred Products

South Carolina Department of Health and Human Services Post Office Box 8206 Columbia, South Carolina

Pharmacy Benefit Management (PBM) Program FORMULARY/PRODUCT RESTRICTIONS

U T I L I Z A T I O N E D I T S

ATYPICAL ANTIPSYCHOTICS

2015 Step Therapy Prior Authorization Medical Necessity Guidelines

2019 STEP THERAPY CRITERIA UCare Individual & Family Plans UCare Individual & Family Plans with Fairview

Sedative Hypnotics. Description

Avoid paying too much for your prescriptions

Sedative Hypnotics. Description

Antipsychotic Medications Age and Step Therapy

Appendix: Psychotropic Medication Reference Tables

Alameda Alliance for Health Pharmacy & Therapeutics (P&T) Committee Decisions

Judges Reference Table for the March 2016 Psychotropic Medication Utilization Parameters for Foster Children

HOSPITAL BASED INPATIENT PSYCHIATRIC SERVICES (HBIPS) MEASURE SET

IOWA MEDICAID DRUG UTILIZATION REVIEW COMMISSION 100 Army Post Road (515)

Drugs requiring prior authorization: the list of drugs requiring prior authorization for this clinical criteria

Step Therapy Group. Atypical Antipsychotic Agents

Antipsychotics Prior Authorization Criteria for Louisiana Fee for Service and MCO Medicaid Recipients

Pharmacy Medical Necessity Guidelines: Atypical Antipsychotic Medications. Effective: December 12, 2017

South Carolina Department of Health and Human Services Post Office Box 8206 Columbia, South Carolina

Pharmacy Medical Necessity Guidelines: Atypical Antipsychotic Medications. Effective: February 20, 2017

Indiana Medicaid Drug Utilization Review Board Newsletter

Comparison of Atypical Antipsychotics

Relative Cost/Month. Less than $10. Loratadine Liquid* $10-$15 Cetirizine liquid 1mg/mL*

Iowa Medicaid Drug Utilization Review (DUR) Commission Meeting March 4, 2009

Pharmacy Medical Necessity Guidelines: Antipsychotic Medications

literature that drug combinations containing butalbital should not be used in treatment of chronic pain and are not appropriate for long term routine

DOD PHARMACY AND THERAPEUTICS COMMITTEE RECOMMENDATIONS INFORMATION FOR THE UNIFORM FORMULARY BENEFICIARY ADVISORY PANEL

Information for Vermont Prescribers of Prescription Drugs. Lunesta (eszopiclone tablets)

MEDICAL ASSISTANCE BULLETIN

A Brief Overview of Psychiatric Pharmacotherapy. Joel V. Oberstar, M.D. Chief Executive Officer

ABILIFY INJ. Products Affected Step 2: ABILIFY MAINTENA PREFILLED SYRINGE 300 MG INTRAMUSCULAR ABILIFY MAINTENA PREFILLED SYRINGE 400 MG INTRAMUSCULAR

The Medical Letter. on Drugs and Therapeutics. Usual Adult Hypnotic Dose 1,2 Some Adverse Effects Comments Cost 3

Step Therapy Requirements. Effective: 03/01/2015

Mercy Care ALBENDAZOLE. Products Affected. ALBENZA TABLET 200 MG ORAL Details. Criteria. Refer to PA Guideline for approval criteria

CONTRAINDICATIONS TABLE

North Dakota Medicaid Therapeutic Duplication Edits

South Carolina Department of Health and Human Services Post Office Box 8206 Columbia, South Carolina

AHCCCS BEHAVIORAL HEALTH DRUG LIST EFFECTIVE OCTOBER 1, 2016

Quarterly Pharmacy Formulary Change Notice

Michael J. Bailey, M.D. OptumHealth Public Sector

See Important Reminder at the end of this policy for important regulatory and legal information.

Slide 1. Slide 2. Slide 3. About this module. About this module. Antipsychotics: The Essentials Module 5 A Primer on Selected Antipsychotics

Buckeye Health Plan Medicaid Criteria Updates Q1 2017

MEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. I. Requirements for Prior Authorization of Antipsychotics

ANTICONVULSANTS. Details. Step Therapy Criteria Date Effective: April 1, 2019

See Important Reminder at the end of this policy for important regulatory and legal information.

Debra Brown, PharmD, FASCP Pharmaceutical Consultant II Specialist. HMS Training Webinar January 27, 2017

LATUDA Commercial Update

FirstCarolinaCare Insurance Company Step Therapy Requirements

Hospice High Dollar Medications and Possible Alternatives

Pharmacy Medical Necessity Guidelines: Antipsychotic Medications

HARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES. SEDATIVE HYPNOTIC AGENTS Generic Brand HICL GCN Exception/Other ZOLPIDEM

See Important Reminder at the end of this policy for important regulatory and legal information.

Attention: Behavioral Health Providers, Pharmacists and Prescribers N.C. Medicaid and N.C. Health Choice Preferred Drug List Changes - UPDATE

QUANTITY LIMIT CRITERIA

STEP THERAPY CRITERIA

Use Brand Only. Preferred Drug Status PRIOR AUTHORIZATION REQUIRED

Pharmacy Medical Necessity Guidelines: Antipsychotic Medications

Step Therapy Criteria

Iowa Medicaid Mental Health Advisory Group Meeting February 13, Tentative Agenda

Lower your costs. Save money with preferred generic and preferred brand-name drugs 2018 Aetna Rx Step Program Medicine List

Texas Standard Prior Authorization Form Addendum

Insomnia Agents (Sherwood Employer Group)

Clinical Policy: Olanzapine Long-Acting Injection (Zyprexa Relprevv) Reference Number: CP.PHAR.292 Effective Date: Last Review Date: 08.

Kentucky Department for Medicaid Services Drug Review and Options for Consideration

Mercy Care Plan. Acyclovir Ointment. Products Affected. acyclovir ointment 5 % external Details. Criteria. Requires use of oral Acyclovir

CENPATICO INTEGRATED CARE BEHAVIORAL HEALTH DRUG LIST BY DRUG NAME. Use Brand Only

Title 19/21 GMH/SA & Non-Title 19/21 SMI Behavioral Health Drug List Updated 05/01/2015

See Important Reminder at the end of this policy for important regulatory and legal information.

Title 19/21 GMH/SA & Non-Title 19/21 SMI Behavioral Health Drug List Updated 4/01/2018

4/2/13 COMMON CLASSES OF MEDICATIONS. Child & Adolescent Behavioral Medicine & Medication Therapies. Behavioral Medicine & Medication Therapies

5-ASA. Products Affected Dipentum 250 mg capsule. Details. Lialda 1.2 gram tablet,delayed release

ALLERGIC CONJUNCTIVITIS AGENTS

Drug Use Criteria: Atypical Antipsychotics (oral)

New Patient Questionnaire

MEDICAID BULLETIN. Providers Indicated

MEDICAL ASSISTANCE BULLETIN

Beneficiary Advisory Panel Handout Uniform Formulary Decisions 23 June 2011

Psychotropic Strategies Handout Package

Step Therapy Program Precision Formulary

Select Inhaled Respiratory Agents

2018 STEP THERAPY CRITERIA UCare Connect (SNBC) MinnesotaCare Prepaid Medical Assistance Program (PMAP) Minnesota Senior Care Plus (MSC+)

TRANSCRANIAL MAGNETIC STIMULATION & BRAIN MUSIC THERAPY

TDMHMR EXECUTIVE FORMULARY COMMITTEE MINUTES April 16, 2004

ABILIFY ABILIFY DISCMELT ACTONEL ACTOPLUS MET ACTOPLUS MET XR ACTOS ADCIRCA ADVAIR DISKUS ADVAIR HFA

MO Medicaid Foster Care Drugs FY10-FY14

News & Views. Maryland Medicaid Mental Health Formulary Revisions. Responsible use of Intervention and Outcome Codes

Title 19/21 GMH/SA & Non-Title 19/21 SMI Behavioral Health Drug List Updated 01/01/2017

Inhaled bronchodilators relax constricted airways and treat the noisy part of asthma: coughing, wheezing, choking and shortness of breath.

North Dakota Medicaid Therapeutic Duplication Edits

Transcription:

South Carolina Department of Health and Human Services Post Office Box 8206 Columbia, South Carolina 29202-8206 Pharmacy and Therapeutics (P&T) Committee Meeting MINUTES 1. Call to Order A meeting of the P&T Committee convened at 4:00 p.m. on Wednesday, May 1, 2013. 2. Welcome Deborah Tapley, R.Ph., called the meeting to order and welcomed members, guests, and staff members. Ms. Tapley opened the meeting by stating that the P&T Committee meetings are held in compliance with the Freedom of Information Act s (FOIA) mandate that the public is notified when the public s business is being done, and that furthermore, the public has been notified that this facility is accessible to individuals with disabilities, and special accommodations could have been provided if requested in advance. 3. Committee Members Present: Deborah Tapley, R.Ph. Jony Bollinger, MD James Lindsey, MD Thomas Phillips, R.Ph. Kelly Jones, PharmD, BCPS Edward Behling, MD Tan Platt, MD SC DHHS Staff: Jim Assey, R.Ph. Janet Giles Marion Burton, MD Shealy Reibold, JD Magellan Medicaid Administration: Lisa Correll, PharmD 4. Discussion Topics A. Committee Meeting Minutes, Wednesday, February 6, 2013. The draft minutes from the previous P&T Committee meeting were emailed to the members so that they could review the document prior to the meeting. The minutes were approved unanimously. P&T Committee Meeting Minutes Page 1 of 5

B. Public Comment Company Speaker Drug/Class Sanofi Pasteur, Inc. Ellen Shannon, PhD, RN Sklice 5% Lotion Pfizer Barbara Phillips, PharmD Lyrica Novartis Pharmaceuticals Sharon Hernandez, PharmD Fanapt Sunovion Pharmaceuticals Lizbhet Delgado, PharmD Latuda AstraZeneca William Pottorf, PhD Seroquel XR Teva Respiratory, LLC Chris Picknell ProAir HFA Speakers gave their time back to the Committee. C. Drug Classes for Review Lisa Correll led the discussion for the following drug classes: Laxatives & Cathartics Antihypertensives, Sympatholytics Antiparasitics, Topical Beta Agonist Agents, Short Acting Oral Agents Neuropathic Pain Antipsychotics, Oral Bronchodilators, Beta Agonist Short Acting Inhalers Bronchocilators, Beta Agonist Long Acting Inhalers Sedative Hypnotics Immunomodulators, Atopic Dermatitis The chart below represents the recommendations from the P & T Committee: Milk of Magnesia Magnesium Citrate Lactulose PEG 3350/Electrolyte MiraLAX OTC LAXATIVES & CATHARTICS Non- Colyte, GoLYTELY, NuLYTELY Kristalose MoviPrep OsmoPrep PEG 3350 OTC PEG 3350 with Flavor Packs Clonidine, Oral Guanfacine, Oral Methyldopa, Oral ANTIHYPERTENSIVES, SYMPATHOLYTICS Non- Catapres Oral Clonidine, Transdermal Clorpres P&T Committee Meeting Minutes Page 2 of 5

Catapres-TTS, Transdermal Methyldopa/HCTZ Reserpine Permethrin, OTC Ulesfia Permethrin 5% Cream ANTIPARASITICS, TOPICAL Non- Eurax, Cream/Lotion Lindane Malathion Natroba Ovide Sklice Spinosad Albuterol Syrup Albuterol IR Tablet BETA AGONIST AGENTS, SHORT ACTING ORAL AGENTS Non- Albuterol Tablet (ER) Metaproterenol Tablet Metaproterenol Syrup Terbutaline Tablet Gabapentin Capsule/Solution Lyrica, Capsule/Solution Savella Dose Pack/Tablets NEUROPATHIC PAIN Non- Gabapentin Tablet Gralise Horizant Lidoderm Patch Neurontin Qutenza Clozapine ODT Fanapt Fazaclo Olanzapine Latuda Risperidone Quetiapine Saphris Seroquel XR Ziprasidone Cap ANTIPSYCHOTICS, ORAL Non- Abilify Clozaril Invega Geodon Olanzapine ODT Risperdal Solution/ODT Seroquel Zyprexa P&T Committee Meeting Minutes Page 3 of 5

BRONCHODILATORS, BETA AGONIST SHORT ACTING INHALERS Non- Proventil HFA Ventolin HFA ProAir HFA Foradil BRONCHODILATORS, BETA AGONIST LONG ACTING INHALERS Non- Arcapta Serevent Diskus Temazepam (15mg, 30mg) Zolpidem IR Chloral Hydrate Covered for children 0-12 years of age only SEDATIVE HYPNOTICS Non- Ambien /CR Doral Edluar Halcion/Triazolam Flurazepam Intermezzo Lunesta Restoril Temazepam (7.5mg, 22.5mg) Silenor Zaleplon Zolpidem ER ZolpiMist Elidel IMMUNOMODULATORS, ATOPIC DERMATITIS Non- Protopic 5. Old Business Jim Assey advised the Committee that the Universal Prior Authorization (PA) form, developed by the CCIG Workgroup, has been finalized and posted on each plan s website. 6. New Business Jim Assey advised the Committee that the open Pharmacy Forum, originally scheduled for Friday, May 3, 2013 was rescheduled to Monday, May 20, 2013 and a SC Medicaid bulletin would be forthcoming. Jim Assey introduced Bryan Amick as the new Pharmacy Director at SC DHHS. P&T Committee Meeting Minutes Page 4 of 5

7. Resolved Items Recommendations regarding PDL status for drugs in the following classes were approved for submission to DHHS. Laxatives & Cathartics Antihypertensives, Sympatholytics Antiparasitics, Topical Beta Agonist Agents, Short Acting Oral Agents Neuropathic Pain Antipsychotics, Oral Bronchodilators, Beta Agonist Short Acting Inhalers Bronchocilators, Beta Agonist Long Acting Inhalers Sedative Hypnotics Immunomodulators, Atopic Dermatitis 8. Closing Comments The next meeting will be held on Wednesday, August 7, 2013, at 4:00 p.m. 9. Adjournment The meeting adjourned at 5:35 p.m. P&T Committee Meeting Minutes Page 5 of 5